A Phase I, Open-label, Single-dose, Single-arm Trial to Investigate Metabolism and Pharmacokinetics of BI 456906 (C-14) Administered Subcutaneously to (Otherwise) Healthy Male Volunteers With Normal Body Weight, Overweight or Obesity
Latest Information Update: 20 Dec 2022
At a glance
- Drugs Survodutide (Primary)
- Indications Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 22 Sep 2022 Status changed from active, no longer recruiting to completed.
- 30 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 15 Jul 2022 Planned End Date changed from 17 Oct 2022 to 22 Sep 2022.